Agenda

This year’s theme:

“Financing, Commercialisation, & Collaboration: opportunities in Central Europe”

Agenda correct on 19 October 2014

22 October 2014   

18.00

Registration open

18.00

Pre-conference Drinks Reception at the Hotel Stary

 

23 October 2014 

MAIN CONFERENCE STARTS

08.00 Registration Open

09.45

Welcome
Leszek Grabarczyk, The National Centre for Research and Development; NCBR (Poland)

Roland Kozlowski, LSBC (Poland)

10.00 Session: Some perspectives on life science investment

Chair: Roland Kozlowski

10.00

Talk: Early stage life science investment, positive and negative experiences in Western Markets

Catherine Beech (UK)

10.30

Talk: Clinical trials in Poland and Central Europe – case studies, problems and solutions

Mariusz Olejniczak (Assign Clinical Research Sp. z o.o., Poland)

11.00 Coffee & Networking


11.45 Session: Private-public partnership and seeding innovation: first blossoms emerge

Chair: Roland Kozlowski

11.45

Talk: Bridge VC Leszek Grabarczyk

The National Centre for Research and Development; NCBR (Poland)

12.00

Talk: The role of the Polish Agency for Enterprise Development in funding innovation.
Michal Banka, The Polish Agency for Enterprise Development (Poland)

12.15

Investment opportunities:

Four Investment opportunities emerging from the Bridge VC program Presented by LSBC:

Roland Kozlowski (Brief Overview)

Krzysztof Jakubczak (devices)

Marta Osęka (devices)

Maciej Paszewski (therapeutics)

Edyta Niemczyk (diagnostics)


13.15 Networking lunch

14.15 Session: Science parks and incubators estate agencies or hot-beds of innovation?

           Chair & Fireside Discussion Host: Marcin Szumowski

 

Talk: Incubator case study

Glenn Crocker (Biocity; UK)

14.45

Fireside discussion: What works and what doesn’t lessons from established players

Benjamin Thiering (Berlin Partner, Germany)

Glenn Crocker (CEO, Biocity; UK)

Łukasz Nieradko (Wroclaw Research Centre EIT+; Poland)

15.30

TEA & Networking

16.15

Panel Discussion:Generic or innovative products or innovation in generics what’s best for our region.

Panel Moderator: Steven Powell

Chas Bountra (Structural Genomics Consortium, UK)

Klaus Martin (Polpharma Biologics, Poland)

Bogusław Sieczkowski(Selvita, Poland)

Marek Borzestowski (Giza Polish Ventures, Poland)

Kreske Nickelsen (JPIF, Germany)

17.00

Conference close for the day

19.15

Networking drinks, Conference Dinner, Live Music: Restaurant Pod Roza

24 October 2014

7.45

Innovation is Great - Business Breakfast

Business Breakfast Hosted by UKTI and the British Embassy in Warsaw. How can Polish and UK companies collaborate.

Moderator: Mark Treherne (UK)

 

Session Starts 9.15  Commercialisation and financing

Chair: Catherine Beech

9.15

Talk: Commercialising medical devices

Romeer Fernandes (Switzerland)

9.45

Panel discussion: How to finance, commercialise and generate value from devices

Panel Moderator: Catherine Beech

Regina Hodits (Wellington Partners, Germany)

Romeer Fernandes (Switzerland)

Janusz Golus (Philips Healthcare, Poland)

Marcin Szumowski (Medicalgorithmics, Poland)

10.30

Company Showcase

Presentations from 4 Polish companies seeking to expand their business internationally

Selvita: Bogusław Sieczkowski

Polpharma Biologics: Tomasz Góralczyk                                                                                

BLIRT: Dominik Ziętkowski

Proteon Pharmaceuticals:Jeffery Grady

11.15

Coffee and networking

11.45

Talk: Commercialising platforms and diagnostics

Alex Yule (Alexander Yule Consulting, UK)

12.30

Panel discussion: How to finance, develop and generate value for such opportunities

Moderator: Roland Kozlowski

Mike Romanos (Crescendo Biologics, UK)

Alex Yule (Alexander Yule Consulting, UK)

Andrew Allars (Wyvern Asset Management, UK)

Steven Powell (Gilde, Belgium)

13.15

Summing up & Conference Close

Roland Kozlowski (LSBC)

13.30-15.30

Roundtable discussion for Investors Interested in Investment in innovation in Poland Private Public Partnership opportunities over lunch.

Foreign visitors include: Wywern Asset Management, Giza Venture Capital, Wellington Partners , JPIF, Gilde